Cargando…

Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam

BACKGROUND AND OBJECTIVES: Cytochrome P450 2C9 (CYP2C9) is involved in the biotransformation of many commonly used drugs, and significant drug interactions have been reported for CYP2C9 substrates. Previously published physiologically based pharmacokinetic (PBPK) models of tolbutamide are based on a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perkins, Everett J., Posada, Maria, Kellie Turner, P., Chappell, Jill, Ng, Wee Teck, Twelves, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956062/ https://www.ncbi.nlm.nih.gov/pubmed/29119333 http://dx.doi.org/10.1007/s13318-017-0447-5

Ejemplares similares

Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A‐catalysed hydroxylation by sulfaphenazole
por: Dekker, Stefan J, et al.
Publicado: (2018)

Sulfaphenazole reduces thermal and pressure injury severity through rapid restoration of tissue perfusion
por: Turner, Christopher T., et al.
Publicado: (2022)

Effect of Temperature on Tolbutamide Binding to Glycated Serum Albumin
por: Szkudlarek, Agnieszka, et al.
Publicado: (2017)

Pharmacokinetic Interactions of Herbs with Cytochrome P450 and P-Glycoprotein
por: Cho, Hyun-Jong, et al.
Publicado: (2015)

Pharmacokinetics, toxicity, and cytochrome P450 modulatory activity of plumbagin
por: Sumsakul, Wiriyaporn, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity
por: Xu, Y, et al.
Publicado: (2015)

The potential for interaction of tolbutamide with pomegranate juice against diabetic induced complications in rats
por: Chakraborty, Manodeep, et al.
Publicado: (2017)

In Vitro Investigation of the Interaction of Tolbutamide and Losartan with Human Serum Albumin in Hyperglycemia States
por: Szkudlarek, Agnieszka, et al.
Publicado: (2017)

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
por: Simon, George R., et al.
Publicado: (2011)

Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects
por: Han, Ji Min, et al.
Publicado: (2020)

The Cytochrome P450 Homepage
por: Nelson, David R
Publicado: (2009)

Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450
por: Campelo, Diana, et al.
Publicado: (2018)

Influence of antioxidant (L- ascorbic acid) on tolbutamide induced hypoglycaemia/antihyperglycaemia in normal and diabetic rats
por: Sreemantula, Satyanarayana, et al.
Publicado: (2005)

Evaluation of CYP2C9 Activity in Rats: Use of Tolbutamide Alone and in Combined with Bupropion
por: Qiu, Xiangjun, et al.
Publicado: (2014)

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A
por: Otsuka, Yukio, et al.
Publicado: (2020)

Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics
por: Lenoir, Camille, et al.
Publicado: (2021)

Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities
por: Schink, Michael, et al.
Publicado: (2017)

The FMN “140s Loop” of Cytochrome P450 Reductase Controls Electron Transfer to Cytochrome P450
por: Rwere, Freeborn, et al.
Publicado: (2021)

Andrographis paniculata Extract and Andrographolide Modulate the Hepatic Drug Metabolism System and Plasma Tolbutamide Concentrations in Rats
por: Chen, Haw-Wen, et al.
Publicado: (2013)

Fungal cytochrome P450 database
por: Park, Jongsun, et al.
Publicado: (2008)

Cytochrome P450 humanised mice
por: Gonzalez, Frank J
Publicado: (2004)

Intronic polymorphisms of cytochromes P450
por: Ingelman-Sundberg, Magnus, et al.
Publicado: (2010)

The Role of Cytochromes P450 in Infection
por: Stavropoulou, Elisavet, et al.
Publicado: (2018)

Cytochromes P450, Oxygen, and Evolution
por: Lewis, David F.V., et al.
Publicado: (2001)

Correlation of Cytochrome P450 Oxidoreductase Expression with the Expression of 10 Isoforms of Cytochrome P450 in Human Liver
por: Zhang, Hai-Feng, et al.
Publicado: (2016)

1-Aminobenzotriazole: A Mechanism-Based Cytochrome P450 Inhibitor and Probe of Cytochrome P450 Biology
por: de Montellano, Paul R Ortiz
Publicado: (2018)

Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain
por: Burris-Hiday, Sarah D., et al.
Publicado: (2023)

Contribution of Cytochrome P450 and ABCB1 Genetic Variability on Methadone Pharmacokinetics, Dose Requirements, and Response
por: Fonseca, Francina, et al.
Publicado: (2011)

Modulation of Hepatic Cytochrome P450 Enzymes by Curcumin and its Pharmacokinetic Consequences in Sprague–dawley Rats
por: Kim, Sang-Bum, et al.
Publicado: (2015)

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
por: Imamura, Chiyo K., et al.
Publicado: (2015)

Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats
por: Na, Young-Guk, et al.
Publicado: (2019)

Polymorphisms in Cytochrome P450 are associated with Extensive Efavirenz Pharmacokinetics and CNS Toxicities in an HIV Cohort in Botswana
por: Vujkovic, Marijana, et al.
Publicado: (2018)

The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
por: Furuse, Maizumi, et al.
Publicado: (2021)

Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients
por: Htun, Yi Yi, et al.
Publicado: (2020)

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling
por: Posada, Maria M., et al.
Publicado: (2020)

Cytochrome P450 1A2 Is Incapable of Oxidizing Bilirubin Under Physiological Conditions
por: Li, Xinyi, et al.
Publicado: (2019)

Cytochrome P450-Mediated Phytoremediation using Transgenic Plants: A Need for Engineered Cytochrome P450 Enzymes
por: Kumar, Santosh, et al.
Publicado: (2012)

Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model
por: Jing, Jing, et al.
Publicado: (2022)

A comprehensive evaluation in clinic and physiologically‐based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450–mediated drug–drug interaction potential for pomotrelvir
por: Yang, Ziping, et al.
Publicado: (2023)

Fungal Cytochrome P450s and the P450 Complement (CYPome) of Fusarium graminearum
por: Shin, Jiyoung, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a523jailukvrmn9hbr12v8aaa2